Document Detail

Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer.
MedLine Citation:
PMID:  14566838     Owner:  NLM     Status:  MEDLINE    
The FHIT tumor suppressor gene, which encompasses the fragile site FRA3B at 3p14.2, is altered frequently in many types of human cancers. To determine its importance as a prognostic marker in breast cancer, the expression of the FHIT protein was studied in a series of 452 breast carcinomas by using immunohistochemistry on sections of tissue microarrays. Three distinct levels of FHIT expression were observed: in 154 cases (34.1%) expression was unchanged as compared to normal level; in 78 (17.2%) no expression was found; in the remaining 220 cases (48.7%), expression was intermediate. Overall, two-thirds of the cases had abnormal levels of the protein. Absence of FHIT was significantly associated with a higher grade (p < 0.01) and absence of hormone receptors (p < 0.001). The patients were separated into Group I (153 node-negative good prognosis patients who did not receive adjuvant chemotherapy) and Group II (226 high-risk patients treated by adjuvant chemotherapy) according to the St.-Gallen conference consensus. The median follow-up was 48 months. Among Group I but not Group II patients, a multivariate analysis showed that FHIT expression was significantly associated with disease-free survival. The relative risk of recurrence for FHIT-negative Group I patients was 2.37 (1.21-4.64; p = 0.03). Thus, among the patients who present with tumors of apparent good prognosis, FHIT is an independent prognostic factor that distinguishes a subgroup of patients who could benefit from adjuvant treatment.
Christophe Ginestier; Valérie-Jeanne Bardou; Cornel Popovici; Emmanuelle Charafe-Jauffret; François Bertucci; Jeannine Geneix; José Adélaïde; Max Chaffanet; Jacques Hassoun; Patrice Viens; Jocelyne Jacquemier; Daniel Birnbaum
Related Documents :
8093668 - P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemothe...
15867228 - Cd44 expression is associated with increased survival in node-negative invasive breast ...
16206298 - Long-term disease-free survival of patients with radically resected thymomas: relevance...
15897568 - Carbonic anhydrase ix expression predicts outcome of interleukin 2 therapy for renal ca...
21080748 - Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small-...
24238048 - Operative intervention for recurrent adrenocortical cancer.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  107     ISSN:  0020-7136     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2003 Dec 
Date Detail:
Created Date:  2003-10-20     Completed Date:  2004-02-18     Revised Date:  2007-07-24    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  854-62     Citation Subset:  IM    
Copyright Information:
Copyright 2003 Wiley-Liss, Inc.
Département d'Oncologie Moléculaire, Institut Paoli-Calmettes and U119 INSERM, IFR57, Marseille, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acid Anhydride Hydrolases*
Breast Neoplasms / genetics*,  mortality,  pathology*,  therapy
Gene Deletion*
Genes, Tumor Suppressor*
Lymphatic Metastasis
Middle Aged
Neoplasm Invasiveness
Neoplasm Proteins / genetics*
Oligonucleotide Array Sequence Analysis
Reproducibility of Results
Survival Analysis
Time Factors
Tumor Markers, Biological / analysis
Reg. No./Substance:
0/Neoplasm Proteins; 0/Tumor Markers, Biological; 0/fragile histidine triad protein; EC 3.6.-/Acid Anhydride Hydrolases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-...
Next Document:  Identification of a sperm protein 17 CTL epitope restricted by HLA-A1.